Search

Bio Roundup: Eli Lilly Tries Tau, Generic Insulin, NASH Cash & More

BIO ROUNDUP: ELI LILLY TRIES TAU, GENERIC INSULIN, NASH CASH & MORE

Pharmaceutical industry critics lament the cost of rare disease drugs, but some of the steepest price hikes have come on widely used...

 
 
 

BIG PHARMA RIVALS PFIZER AND NOVARTIS TEAM UP ON NASH COMBO TARGETS

Pfizer is joining forces with Novartis with a "throw it all at the wall and see what sticks" approach as they look to combine NASH...

 
 
 

ESMO18: NOVARTIS PI3K COMBO THERAPY BOOSTS SURVIVAL IN SUBSET OF BREAST CANCER PATIENTS

Novartis has come out with data at this year's European cancer congress ESMO with positive results from a phase 3 looking at its investigational...

Bio Roundup: Prices on TV, Novartis Hearts Radio, Warp Drive's End

BIO ROUNDUP: PRICES ON TV, NOVARTIS HEARTS RADIO, WARP DRIVE'S END

Two new battlegrounds emerged this week in the nation's ongoing drug pricing debate. The first involved television: The federal government...

 
 
 
Cancer-therapy provider Endocyte spikes 50% after Novartis agrees to buy it for $2.1 billion

CANCER-THERAPY PROVIDER ENDOCYTE SPIKES 50% AFTER NOVARTIS AGREES TO BUY IT FOR $2.1 BILLION

Novartis , the Swiss drug maker, has agreed to buy the US cancer-treatment provider Endocyte , for $2.1 billion. Under the agreement,...

What It's Really Like To Live With Metastatic Breast Cancer

WHAT IT'S REALLY LIKE TO LIVE WITH METASTATIC BREAST CANCER

Branded - Novartis: Cancer Can Kiss This Episode 1 Breast cancer awareness is so much more than pink ribbons, painted bras, and feather...

 
 
 
Bio Roundup: Nobel Prizes, Duchenne Steps, Guardant's IPO & More

BIO ROUNDUP: NOBEL PRIZES, DUCHENNE STEPS, GUARDANT'S IPO & MORE

Cancer immunotherapy is all the rage these days. The idea of harnessing the immune system to treat cancer has sparked billions of dollars...

NOVARTIS-BACKED CELL THERAPY STARTUP GAMIDA FILES FOR IPO

Gamida Cell has filed to raise $69 million in a Nasdaq IPO. The Novartis-backed cell therapy player wants the money to wrap up a phase...

 
 
 
Drugmakers are using an unusual tactic to compete in a new class of medication - giving it away for free

DRUGMAKERS ARE USING AN UNUSUAL TACTIC TO COMPETE IN A NEW CLASS OF MEDICATION - GIVING IT AWAY FOR FREE

Since May, the FDA has approved three new drugs in a new class of preventive migraine medication: Aimovig, made by Amgen and Novartis;...

Bio Roundup: Amarin's Stunner, Lung Cancer News, Data Dumps & More

BIO ROUNDUP: AMARIN'S STUNNER, LUNG CANCER NEWS, DATA DUMPS & MORE

Six years ago, a biotech called Amarin won FDA approval of a prescription fish-oil pill, Vascepa, because it could lower triglycerides,...

 
 
 

SALES SPECIALIST- MS - SAN DIEGO CA - NOVARTIS - SAN DIEGO, CA

2 years was in a specialty pharmaceutical /biotech sales within the last 5 years. Interpersonal communication, organization & prioritization,...

 
 
 
In-house CAR-T manufacturing preferable to outsourcing, execs say

IN-HOUSE CAR-T MANUFACTURING PREFERABLE TO OUTSOURCING, EXECS SAY

Keeping manufacturing close to home allows for greater flexibility, lower long-term costs and building up native manufacturing capability,...

Bio Roundup: A Gene Editing 1st, China Rises, Schenkein Steps Away

BIO ROUNDUP: A GENE EDITING 1ST, CHINA RISES, SCHENKEIN STEPS AWAY

If you're still recovering from a Labor Day hangover or busy searching for the identity of the anonymous writer of the anti-Trump op-ed...

 
 
 
Subject CAR-Ts to price competition or randomized trials to ensure even coverage, expert says

SUBJECT CAR-TS TO PRICE COMPETITION OR RANDOMIZED TRIALS TO ENSURE EVEN COVERAGE, EXPERT SAYS

CMS could run trials of CAR-Ts in lymphoma if unsure of their similarity on benefit to patients and ancillary service costs, Dr. Peter...